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The hyphal wall protein 1 (HWP1) gene of Candida albicans encodes for a fungal cell wall protein,
required for hyphal development and yeast adhesion to epithelial cells; yet, its role in pathogenesis
remains largely unknown. In the present study, we analyzed two C. albicans laboratory strains, the
DAY286 (HWP1/HWP1) and the null mutant FJS24 (hwp1/hwp1) and six clinical isolates [3 harbouring the
homozygous HWP1 gene (HWP1/HWP1) and 3 the heterologous gene (HWP1/hwp1)]. Bioﬁlm production,
fungal HWP1 mRNA levels and ultrastructural morphology were investigated; also, the susceptibility of
these strains to microglial cells was evaluated, in terms of fungal damage and immune cell-mediated
secretory response. When comparing the two laboratory strains, bioﬁlm was produced to a similar
extent independently on the genetic background, while the susceptibility to microglial cell-mediated
damage was higher in the hwp1/hwp1 mutant than in the HWP1/HWP1 counterpart. Also, trans-
mission electron microscopy revealed differences between the two in terms of abundance in surface
adhesin-like structures, fungal cell wall shape and intracellular granules. When comparing the clinical
isolates grouped according to their HWP1 genotype, reduced bioﬁlm production and increased suscep-
tibility to microglial cell-mediated damage occurred in the HWP1/hwp1 isolates with respect to the
HWP1/HWP1 counterparts; furthermore, upon exposure to microglial cells, the HWP1/HWP1 isolates, but
not the HWP1/hwp1 counterpart, showed enhanced HWP1 mRNA levels. Finally, both laboratory and
clinical isolates exhibited reduced ability to stimulate TNFa and nitric oxide production by microglial
cells in the case of heterozygous or null mutant HWP1 genotype.
Overall, these data indicate that C. albicans HWP1 genotype inﬂuences pathogen morphological
structure as well as its interaction with microglial cells, while fungal bioﬁlm production results unaf-
fected, thus arguing on its role as virulence factor that directly affects host mediated defences.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Candida albicans, a commensal of human mucosa in healthy
people, behaves as an opportunistic pathogen in critical patients,
where it causes deep-seated life-threatening infections [1]. In
particular, invasive candidiasis (IC) affects 9% of patients in the
intensive care units and 2e20% of preterm newborns, with as, Clinical and Public Health
ituti Biologici, Via Campi 287,
9 059 205 5483.
ardizzoni.andrea@unimore.itmortality ranging from 20 to 50% [2,3]. Medical devices, such as
cardiovascular and urinary catheters, dialysis access and ven-
triculoperitoneal shunts are considered to be a crucial point of
entry for Candida in these clinical settings [4e6], where, though
relatively rare, meningoencephalitis may also occur as a severe
complication of deep-seated candidiasis [2,3,7]. To date, little is
known on the events driving the onset of such deep-seated in-
fections; increasing attention is being focused on fungal capacity to
produce bioﬁlm directly onto medical devices as a ﬁrst and critical
step towards host invasion [8,9].
In line with this, initial evidence indicates that bioﬁlm-
producing C. albicans isolates are less susceptible to host innate
Glossary
HWP1 hyphal wall protein 1
HWP1/HWP1 strain harbouring the homozygous HWP1
genotype
HWP1/hwp1 strain harbouring the heterozygous HWP1
genotype
hwp1/hwp1 null mutant strain for HWP1 gene
IMH3 inosine-50-monophosphate dehydrogenase
fragment
NO nitrite
OD optical density
PBS phosphate-buffered saline
CV crystal violet
XTT 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide
YPD yeast peptone dextrose medium
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Thus, bioﬁlm formation is assumed to work as an immune escape
mechanism that, in conjunction with reduced susceptibility to
antifungal agents, may greatly support the persistence of implant-
associated C. albicans infections [6]. Moreover, it has been recently
shown that Candida bioﬁlm can act in vitro as a reservoir of infec-
tious viruses [12] further expanding the potential implications of
fungal bioﬁlms in clinical settings.
Numerous C. albicans gene products have been identiﬁed as
relevant to bioﬁlm development onto abiotic surfaces in vitro
[13,14], while information on genes that enable bioﬁlm formation
in vivo has begun to emerge only recently [15,16]. A library of
C. albicans mutants, defective in speciﬁc genetic traits, has been
partially screened [13]; by this approach, several genes including
BCR1, ALS1, ALS3, ECE1 and HWP1, have been shown to be
required for bioﬁlm formation [16,17]. In particular, the gene
HWP1 is known to encode a major C. albicans protein involved in
several functions, including cell wall assembly, intracellular sig-
nalling and hyphal development; moreover, HWP1 promotes
binding of Candida to epithelial cells, as the initial step of colo-
nization [18e24]. Furthermore, some evidence exists on the
pathogenic role of HWP1 in vivo; indeed, as assessed by a murine
model of systemic candidiasis, it has been shown that the het-
erologous and the null mutant strains exhibit reduced and no
virulence, respectively, when compared to the wild type control
strain [19,25].
Not only Candida, with its plethora of ﬁnely regulated virulence
traits, but also the ﬁrst line host defences critically impact on the
onset and outcome of candidiasis. Initial studies provided relevant
information on the role of brain macrophages in the control of
meningoencephalitis. In particular, by a murine model of intrace-
rebral infection, it has been shown that microglial cells exert a
protective role [26], through efﬁcient phagocytosis and anti-
Candida activity, whose biomolecular mechanisms have partially
been deﬁned [27e30]. Furthermore, microglial cell-mediated de-
fences are affected by C. albicans peculiarities, such as the genotype
proﬁle (b versus c) and the dimorphic transition from yeast-to-
hyphal form [31e33].
Here, by means of two C. albicans laboratory strains (the refer-
ence strain DAY286 and its isogenic hwp1/hwp1 mutant, FJS24
strain) and six clinical isolates (3 harbouring the homozygous
HWP1/HWP1 genotype and 3 the heterozygous HWP1/hwp1), the
role of HWP1 genotype has been evaluated in terms of bioﬁlm
production and Candida-microglial cells interaction.2. Materials and methods
2.1. C. albicans
We used two laboratory strains: the reference DAY286 (HWP1/
HWP1) and its isogenic engineered counterpart, the null mutant
FJS24 (hwp1/hwp1) [13,16]; such strains were purchased from the
Fungal Genetics Stock Center (Kansas City, Missouri, USA) [34]. We
also used six clinical isolates of C. albicans, recently collected during
an Italian National Survey on invasive fungal infections [35]; such
isolates had been characterized according to their HWP1 gene
polymorphism [36]. In particular, three isolates (lab names: Ca50vr,
Ca23tv and Ca4no) harboured the homozygous genotype HWP1/
HWP1 and three isolates (laboratory names: Ca24ba, Ca48va and
Ca17vr) were bearing the heterozygous genotype HWP1/hwp1.
Long-term storage of the isolates was carried out in 20% glycerol
at 80 C. Before testing, a loopful of cells from stock cultures were
inoculated in yeast peptone dextrose liquid medium (YPD, Oxoid,
Hampshire, UK) and incubated overnight in an orbital shaker at
30 C. Then, yeast cells were washed twice with sterile phosphate-
buffered saline (PBS, EuroClone, Wetherby, UK), counted and sus-
pended in medium at the desired concentration (105 or 106 cells/
ml).
2.2. Cell lines
The previously established murine microglial cell line BV2 [31]
and the K562 erythroid cell line were maintained by biweekly
passages in RPMI 1640 (Gibco, Grand Island, NY, USA), supple-
mented with 10% heat inactivated foetal bovine serum (Deﬁned
Hyclone, Logan, Utah, USA), 50 mg/ml gentamicin (EuroClone) and
2 mM L-glutamine (EuroClone), hereafter referred to as complete
medium. Experimental cultures were set at a concentration of
5  105 cells/ml in complete medium on the day before each
experiment.
2.3. Bioﬁlm formation
Bioﬁlm formation was obtained on 96-well culture plates, ac-
cording to a previously described protocol [37] with minor modi-
ﬁcations. Brieﬂy, C. albicans yeast cells (105 cells/ml) were
incubated at 37 C for 24 h, in complete medium and in presence of
5% CO2. Then, bioﬁlm production was evaluated by crystal violet
(CV) assay or 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide (XTT, Sigma, St Louis, MO, USA) reduction
assay, as detailed elsewhere [37]. For the CV assay, absorbance was
measured spectrophotometrically by the SunRise Microplate
Reader (Sunrise, Tecan, Salzburg, Austria) at 540 nm optical density
(OD540) and the colour intensity was proportional to bioﬁlm
biomass. For the XTT assay, the absorbance was measured spec-
trophotometrically at 450 nmwith 620 nm as referencewavelength
and the results, expressed as OD450/620, were correlated with
cellular metabolic activities within the bioﬁlm. Each sample was
assessed in 6-replicates.
2.4. Effects of microglial cells on C. albicans bioﬁlm formation
In order to assess the effects of microglial cells on bioﬁlm for-
mation, complete medium and BV2 cells (105 cells/ml) were added
to C. albicans yeast cells that had been pre-incubated at 37 C in 5%
CO2 for 3 h. In parallel groups, K562 cells (105 cells/ml) were added
as controls. Operationally, the 3 h pre-incubationwas performed to
allow fungal adhesion, as initial step in bioﬁlm production. After
additional 24 and 48 h incubation, microglial cells were lysed
hypotonically, fungal bioﬁlm formation (mass) and its metabolic
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Fig. 1. Bioﬁlm production by C. albicans strains DAY286 (reference) and hwp1/hwp1
(mutant). Yeast cells (105 cells/ml), were pre-incubated for 3 h (in complete medium
and in 5% CO2), then BV2 cells were added (106 cells/ml). After 24 and 48 h of incu-
bation, CV assay was performed. Columns represent the range of OD540 values. SD are
also shown.
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presence or absence of BV2 and of K562 cells. Results were
expressed as OD values (CV and XTT assays). Moreover, based on
the literature [10], the percentage of fungal damage was calculated
employing the data obtained with the XTT assay, according to the
formula: 100  [1  (ODCandida þ BV2/ODCandida alone)].
2.5. Assessment of fungal gene expression
C. albicans yeast cells (106 cells/ml) were pre-incubated in 25 ml
cell culture ﬂasks in complete medium at 37 C, in presence of 5%
CO2, for 3 h. Then, BV2 cells (106 cells/ml) or complete medium
were added and the ﬂasks were further incubated. After 1 h,
microglial cells were lysed hypotonically and RNA was extracted
using the TRIzol reagent (Invitrogen, CA, USA), according to
manufacturer protocol. Then, purity and concentration of RNA ex-
tracts were measured by a NanoDrop 2000 Spectrophotometer
(Thermo Fisher Scientiﬁc, Wilmington, DE, USA) and up to 2 ng
were retrotranscribed by the High Capacity RNA-to-cDNA Kit
(Applied Biosystems, Foster City, CA, USA), in a ﬁnal volume of 25 ml.
Quantitative real-time PCR was performed in 48 well plates using
the ABI StepOne apparatus (Applied Biosystems) and the Fast SYBR
Green Master Mix (Applied Biosystems). Two primer sets were
designed for the target gene HWP1 and the housekeeping gene
inosine-50-monophosphate dehydrogenase fragment (IMH3) using
the Primer Express 2.0 software (Applied Biosystems); primer se-
quences were as follows:
HWP1 (50-TGCTATCGCTTATTACATGTTATC-30, and 50-
GAGCTTCTTCTGTTTCACCTTGACe30);
IMH3 (50-TATTCATATGGCATTATTGGGTGGTA-30, and 50-AAC-
CATTTCTGCTTGTTCTTCAGA-30).
The relative expression levels were calculated using the 2DDCt
method. The control gene IMH3 was used to normalize the results.
2.6. Cytokine measurement and nitric oxide determination
Assays were performed as previously detailed [33]. Brieﬂy,
C. albicans yeast cells, 105 cells/ml in 24-well plates, were pre-
incubated for 3 h in complete medium at 37 C and in presence
of 5% CO2. Then, BV2 cells (106 cells/ml) or LPS (1 mg/ml, Sigma), the
latter used as a positive control, were added to yeast cultures for
additional 6 and 24 h. Supernatants were then collected and
assayed for TNFa content, by ELISA (R&D Systems, Minneapolis,
USA) according to manufacturer’s recommendations. The reaction
was read using the SunRise Microplate Reader (OD450/540). Each
sample was run in triplicate and results were expressed as pg/ml of
cytokine. In parallel, the concentration of nitrite (NO) in the same
supernatants was also measured using the Griess reagent, as pre-
viously described [33].
2.7. Transmission electron microscopy (TEM)
Samples for TEM analysis were processed as detailed elsewhere
[38]. In particular, C. albicans yeast cells (106 cells/ml) were pre-
incubated in 6 well plates in complete medium at 37 C, in pres-
ence of 5% CO2, for 3 h. Then, BV2 cells (106 cells/ml) or complete
medium were added and incubation was carried out for further
24 h. Then, monolayers were washed with PBS, scraped and
centrifuged at 10,000 g. The resulting pellets were ﬁxed overnight
with 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatﬁeld,
PA, USA) in Tyrode’s buffer (Electron Microscopy Sciences), post-
ﬁxed for 2 h in 1% osmium tetroxide (Electron Microscopy Sci-
ences), dehydrated and embedded in Spurr resin (Electron Micro-
scopy Sciences). Semi-thin sections, obtained through the whole
thickness of the pellets, were stained with toluidine blue andobserved with a Zeiss Axiophot (Carl Zeiss, Jena, Germany) light
microscope. Ultrathin sections were stained with uranyl acetate
and lead citrate and observed with a JEM 2010 (Jeol, Tokyo)
transmission electron microscopy.
2.8. Statistical analysis
Statistical analysis was performed by the Student’s t-test. Data in
ﬁgures and table are expressed as mean or median
values  standard deviation (SD) or standard error (SE) of three to
ﬁve independent experiments, unless otherwise speciﬁed.
3. Results
3.1. Bioﬁlm production by the DAY286 (reference) and the FJS24
hwp1/hwp1 mutant strains
To assess the involvement of the HWP1 genotype on bioﬁlm
production, two widely described laboratory strains [13,16], the
DAY286 (reference) and its hwp1/hwp1 mutant (FJS24), were
investigated according to the protocols described in Materials and
methods. Initially, the two strains were investigated for their abil-
ity to produce bioﬁlm, according to previously established pro-
tocols [37]. As assessed by CV assay (Fig. 1), both strains achieved
high and comparable levels of OD540 after 24 h in complete me-
dium. Moreover, no signiﬁcant changes/differences in OD540 levels
were observed after 48 h. Similar patterns of results, conﬁrming no
differences between the two strains, were also observed in parallel
groups, as assessed by the XTT assay (data not shown).
3.2. Impact of microglial cells on DAY286 (reference) and hwp1/
hwp1 mutant strains
The impact of BV2 microglial cells on bioﬁlm formation by the
two laboratory strains was evaluated. Brieﬂy, C. albicans yeast cells
were pre-incubated for 3 h in complete medium; then, BV2 cells
were added and the plates incubated for additional 24 or 48 h. At
each time point, the XTT assay was performed and the results were
then expressed as percent of fungal damage by microglial cells,
according to the established protocols [10]. As detailed in Fig. 2a,
signiﬁcant differences occurred between the two strains in terms of
susceptibility to BV2 microglial cells; in particular, the null mutant
showed levels of microglial cell-mediated damage signiﬁcantly
Fig. 2. Fungal damage induced by BV2 but no by K562 cells on C. albicans bioﬁlm. Yeast
cells (105 cells/ml), were pre-incubated for 3 h (in complete medium and in presence of
5% CO2), then medium or cells (106 cells/ml) were added. After 24 and 48 h of incu-
bation, XTT assay was performed. Box-plots represent the percentage of fungal dam-
age, calculated according to the formula reported in Materials and methods section,
when Candida cells were exposed to BV2 (a) or to K562 cells (b). SD are also shown.
Asterisks denote statistically signiﬁcant difference, (*) p  0.05.
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versus 37% at 48 h, respectively. When in parallel groups, the non-
immuno-competent cell line K562was included as negative control
(Fig. 2b), no fungal damage was observed either at 24 or 48 h of
incubation.
To further investigate the phenomenon, morphological analysis
was performed. As detailed in Fig. 3, TEM images of Candida alone
(incubated for 24 h in complete medium) revealed abundant and
expanded adhesin-like structures on the surface of the DAY286
cells (Fig. 3a) but not on cells of the null mutant strain (Fig. 3b).
Remarkable differences were also evident in terms of cell walls,
which appeared loose and less compact in the null mutant strain
with respect to the reference strain (see inserts in Fig. 3a and b).
Furthermore, as assessed by optical microscopy (Fig. 4), after 24 h of
co-culture, microglial cells appeared profoundly damaged, irre-
spective of the contact with either DAY286 (Fig. 4a) or hwp1/hwp1
(Fig. 4b) Candida cells, while hyphal forms were more abundant in
the DAY286 (Fig. 4a). In addition, large-size intracellular granules
were especially evident in the reference strain (Fig. 4a vs b).
3.3. Bioﬁlm production by HWP1/HWP1 and HWP1/hwp1 clinical
isolates and their susceptibility to microglial cells
The C. albicans clinical isolates, three harbouring the HWP1/
HWP1 and three the HWP1/hwp1 genotypes, were compared fortheir capacity to form bioﬁlmwhen grown in complete medium. As
assessed by the XTT assay (Fig. 5a), the HWP1/HWP1 isolates dis-
played OD540 levels signiﬁcantly higher than the HWP1/hwp1
counterparts (p < 0.05); the phenomenon was evident and
consistent both at 24 and 48 h; a similar trend of results was
observed also by the CV assay (data not shown). Furthermore, the
same C. albicans isolates were investigated for their susceptibility to
microglial cells. Thus, C. albicans yeast cells were pre-incubated for
3 h in complete medium; then, microglial cells were added and the
plates incubated for additional 24 or 48 h. At each time point, the
XTT assay was performed and the results were then expressed as
percent of fungal damage by microglial cells. As detailed in Fig. 5b,
fungal damage was signiﬁcantly higher in the HWP1/hwp1 isolates
than in the HWP1/HWP1 counterparts at both time points (54% vs
26% at 24 h and 45% vs 20% at 48 h, respectively).
To better understand the interaction of the clinical isolates with
the BV2 cells, these isolates were investigated by RT-PCR for the
relative levels of HWP1 gene expression in the presence and in the
absence of microglial cells. Brieﬂy, C. albicans yeast cells (106 cells/
ml) were pre-incubated for 3 h in complete medium. Then, com-
plete medium or BV2 cells (106 cells/ml) were added and the cul-
tures were further incubated for 1 h. The relative levels of HWP1
gene expression are showed in Fig. 5c. A consistent up-regulation of
HWP1 mRNA levels occurred in the group of HWP1/HWP1 isolates
incubated in the presence of microglial cells compared to the
control group (Candida alone). By contrast, HWP1/hwp1 isolates
showed a limited though consistent down-regulation in the pres-
ence of microglial cells.
3.4. Microglial cell secretory response to C. albicans laboratory
strains and clinical isolates
Finally, the proﬁle of microglial cell secretory response to both
laboratory strains and clinical isolates was investigated, according
to previously established protocols [10,33]. Brieﬂy, yeast cells were
pre-incubated in complete medium for 3 h; then, BV2 cells were
added for additional 6 and 24 h. In parallel groups, BV2 cells were
exposed to LPS, used as positive control. Supernatants were har-
vested and assessed for TNFa and NO content. Table 1 shows TNFa
and NO production by BV2 cells exposed to the two laboratory
strains, the DAY286 and the mutant FJS24, and two clinical isolates,
Ca50vr and Ca24ba, representative of the HWP1/HWP1 and HWP1/
hwp1 genotypes, respectively. As expected, LPS greatly enhanced
TNFa production by BV2 cells, withmaximal levels being reached at
6 h. A time-dependent production of TNFa was also observed in
BV2 cells exposed to Candida isolates. In particular, both DAY286
and Ca50vr (HWP1/HWP1) induced levels of TNFa signiﬁcantly
higher than their counterparts, the mutant FJS24 and Ca24ba
(HWP1/hwp1). Concerning NO production, a signiﬁcant increase
occurred, at 24 h, only in BV2 cells exposed to DAY286 and Ca50vr
(HWP1/HWP1).
4. Discussion
Here, by means of laboratory isogenic strains and clinical iso-
lates, we show that C. albicans HWP1 genotype does not affect
bioﬁlm formation in vitro, but rather it inﬂuences fungal suscepti-
bility to microglial cells.
Increasing literature is being provided on fungal genetic traits
that are possibly involved in bioﬁlm formation and virulence
[13,15e17]; construction of laboratory mutant strains as well as
genotyping of clinical isolates has allowed direct associations be-
tween certain phenotypic peculiarities/functions and speciﬁc
genotypic elements [19,20]. In particular, theHWP1 gene appears to
be involved in several pathogenic steps, including adherence to
Fig. 3. Ultrastructural morphology of C. albicans strains DAY286 (reference) and hwp1/
hwp1 (mutant). Yeast cells (106 cells/ml), incubated for 24 h (in complete medium and
in presence of 5% CO2), were ﬁxed and embedded in resin to allow observation of
ultrathin sections by TEM. Representative image of (a) DAY286 reference strain and (b)
hwp1/hwp1 mutant strain. Bar ¼ 1 mm.
Fig. 4. Morphology of 24 h-old Candida-microglial cells co-cultures. C. albicans DAY286
(reference) and FJS24 (hwp1/hwp1 mutant), at the 106 cells/ml cell density, were pre-
incubated for 3 h (in complete medium and in 5% CO2), then BV2 cells were added
(106 cells/ml). After 24 h of incubation, samples were ﬁxed and embedded in resin.
Semi-thin sections were examined by light microscopy. Representative images of (a)
DAY286 reference strain and (b) hwp1/hwp1 FJS24 mutant strains, both exposed to BV2
cells. Bar ¼ 10 mm.
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National Survey Study on invasive fungal infections, we obtained
and partially characterized a collection of 142 clinical C. albicans
isolates, whose proﬁles of HWP1 genotype, bioﬁlm production and
antifungal drug susceptibility have been investigated [35]. Also,
initial information has been provided on the relationship between
ability to produce bioﬁlm in vitro and virulence in Galleria mello-
nella [11]. With the aim of more in depth investigating the role of
HWP1 genotype on bioﬁlm formation, the present study has been
conducted employing i) two laboratory strains, the reference
C. albicansDAY286 strain and itsHWP1 null mutant FJS24, and ii) six
clinical isolates, harbouring the HWP1/HWP1 and the HWP1/hwp1
genotype. Preliminarily, Candida strains/isolates have been
compared for their growth rate under different conditions, namely
at different yeast cell concentrations and in the presence of com-
plete medium or YPD, over a 48-h incubation period. As detailed inSupplementary Table S1, although the growth rates appear
different in complete medium or YPD, yet, no statistically signiﬁ-
cant differences have been observed when comparing the DAY286
with its mutant FJS24 or the Ca50vr HWP1/HWP1with the Ca24ba
HWP1/hwp1 clinical isolates. As detailed in Fig.1, the two laboratory
strains produce bioﬁlm to a similar extent, while differences are
evident between HWP1/HWP1 and HWP1/hwp1 clinical isolates,
with the latter being lower bioﬁlm producers (Fig. 5a). In line with
these data, Tsuchimori and coworkers [25] have recently shown
that also other sets of engineered strains, differing in HWP1 geno-
type, exhibit similar propensities to produce bioﬁlm. In contrast,
our results on clinical isolates reveal differences in bioﬁlm forma-
tion between the two groups, operationally clustered in this study
according to their HWP1 genotype. The unexpected discrepancy
observed with the clinical isolates raises the possibility that addi-
tional unexplored genotypic differences between homo- and het-
erozygous HWP1 isolates may be responsible for the different
behaviour, at least in terms of bioﬁlm production. Possibly, a
complete genotypic characterization of the clinical isolates may
Fig. 5. Bioﬁlm production by C. albicans clinical isolates and their susceptibility to microglial cells. Three HWP1/HWP1 and 3 HWP1/hwp1 isolates were assessed. Bioﬁlm production
(a) by yeast cells (105 cells/ml) incubated for 24 and 48 h, in complete medium, was evaluated by CV assay. Box-plots represent the range of OD540 values. For the evaluation of
fungal susceptibility to BV2 cell, yeast cells (105 cells/ml) were pre-incubated for 3 h (in complete medium), then complete medium or BV2 cells were added (106 cells/ml) for 1, 24
or 48 h. After 24 and 48 h of incubation, XTT assay was performed and box-plots represent the percentage of fungal damage (b), calculated according to the formula detailed in
Materials and methods section. In parallel, after 1 h of incubation, yeast RNA was extracted and HWP1 gene expression was evaluated by RT-PCR (c). Box-plots represent the relative
levels of HWP1 mRNA expression. Mean values and SD are also shown. Asterisks denote statistically signiﬁcant differences, (*) p  0.05.
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on previous [25] and present ﬁndings, we favour the conclusion
that HWP1 genotype does not directly affect Candida ability to
produce bioﬁlm in vitro.
Previous studies demonstrate that microglial cells efﬁciently
contrast C. albicans by phagocytosis and killing of the yeast cells
[26,28,33]. Here, we show that such immune cells are also capable
of affecting fungal bioﬁlm and that the extent of such phenomenon
is related to Candida HWP1 genotype; interestingly, the impact of
microglial cells on bioﬁlm production is similar, both in clinical
isolates and laboratory strains. In particular, when exposed to
microglial cells for 24 h, both the engineered hwp1/hwp1 mutant
strain (Fig. 2a) and the heterozygous clinical HWP1/hwp1 isolates
(Fig. 5b) are damaged to a higher extent than their HWP1/HWP1Table 1
TNFa and NO production by BV2 microglial cells exposed to laboratory strains and cliniccounterparts; such differential proﬁles of susceptibility are retained
also at later times (48 h), when the null mutant (Fig. 2a) and the
heterozygous (Fig. 5b) are still signiﬁcantly affected, while the
homozygous, HWP1/HWP1, are no longer susceptible to microglial
cell-mediated damage. Interestingly, non immuno-competent cells,
such as the erythroid cell line K562, fail to exert any deleterious
effect on fungal bioﬁlm production (Fig. 2b), thus further
strengthening the direct role of BV2 cells while other trivial events
such as nutrient limitation or steric cell-to-cell interference may be
ruled out. Overall, by assessing different parameters, namely fungal
biomass andmetabolic activity, the CV and XTTassays unanimously
indicate that Candida bioﬁlm production is signiﬁcantly impaired
by microglial cells. Our present ﬁndings are in line with a previous
study demonstrating that phagocytes can induce bioﬁlm damageal isolates for 6 and 24 h.
C.F. Orsi et al. / Microbial Pathogenesis 69-70 (2014) 20e2726[10]. By contrast, it has been shown that human peripheral blood
mononuclear cells may enhance the ability of C. albicans to form
bioﬁlm [39]. Differences in the experimental protocols employed
(timing, cultural conditions, etc.) and in the immune cell types
investigated may account for the apparent disagreement among
studies aimed at deﬁning the role of phagocytes on fungal bioﬁlm
production.
Here, as assessed by the clinical isolates, only the homozygous
genotypes show a signiﬁcant enhancement of HWP1 mRNA levels,
following Candida exposure to the microglial cells (Fig. 5c). Besides
indicating a different Candida behaviour based on its HWP1 geno-
type, these data also imply the capacity of Candida to re-program its
ownmolecular machinery in response to the insult provided by the
immune cells, at least in terms of HWP1 transcript levels, thus
further supporting the idea that HWP1 should be considered as a
virulence trait. In line with this conclusion, Staab and coworkers
[18] provide initial evidence on the relevance of HWP1 genotype on
Candida adhesion to epithelial cells in vitro.
Concerning the secretory response of microglial cells to
C. albicans, enhanced TNFa and NO production occurs when
employing the homozygous HWP1/HWP1 genotypes, both of labo-
ratory and clinical origin, while little or no response is observed
against the heterozygous or null mutant counterpart (Table 1). In
linewith our previous work [32], we show that C. albicans promotes
an enhanced secretory response by microglial cells.
Whether structural or rather pathogenetic changes are involved,
in such a microglial cell-related response, remains to be investi-
gated. In any case, the present data provide the ﬁrst evidence that
microglial cells secretory response is differently modulated,
depending upon Candida HWP1 genotype.
Finally, morphological analysis reveals several differences be-
tween the HWP1/HWP1 and hwp1/hwp1 Candida cells. In particular,
the former express abundant adhesin-like structures, barely
detectable in the null mutant, within which both cell wall consis-
tency and thickness appear altered (Fig. 3). While expanding pre-
vious morphological data [24,40], these ﬁndings emphasize the
dual role of HWP1 protein, both as a surface adhesion molecule and
as a protein important in maintaining cell wall integrity. Moreover,
here we show that upon Candida-microglial cell co-culture, the
hwp1/hwp1 fungal bodies appear not only less numerous but also
they show reduced intracellular granules (Fig. 4); to our opinion,
such features can be reasonably explained as markers of microglial
cell-induced stress/damage. Thus, taken together, the morpholog-
ical peculiarities and the quantitative data obtained by XTT and CV
assays underline the enhanced susceptibility of the null mutant to
microglial cells.
Initial efforts are beingmade in dissecting the pathogenic role of
HWP1 in candidiasis. By a murine model of oro-esophageal candi-
diasis, HWP1 genotype has been associated with a peculiar
pathogen-mucosal cell interplay [19,41], while HWP1 ablation has
resulted in reduced virulence, as assessed by a systemic candidiasis
model [25,42]. Here, we provide in vitro evidence that HWP1 ge-
notype does not directly inﬂuence Candida ability to produce bio-
ﬁlm, but it signiﬁcantly affects microglial cell-mediated efﬁcacy.
Thus, we may envisage in vivo situations where Candida HWP1
genotype plays a pathogenetic role as soon as the ﬁrst line immune
defences are called up as critical defence players.Author contributions
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